Related Experiment Video
Updated: Jul 19, 2026
07:38
Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
Published on: June 6, 2025
mTOR, translation initiation and cancer
Y Mamane1, E Petroulakis, O LeBacquer
1Department of Biochemistry, McGill Cancer Centre, McGill University, Montreal, Quebec, Canada.
Oncogene
|October 17, 2006
Summary
Messenger RNA (mRNA) translation control is vital for cell metabolism and gene expression. Targeting the PI3K/Akt/mTOR pathway offers promising cancer treatment strategies by inhibiting translation.
Area of Science:
- Molecular Biology
- Cellular Metabolism
- Cancer Therapeutics
Background:
- Control of mRNA translation is a fundamental process in cell metabolism, gene expression, growth, proliferation, and differentiation.
- Translation regulation responds to nutrient availability, hormones, and growth factors, linking it to cell cycle progression.
- The PI3K/Akt/mTOR pathway significantly influences mRNA translation via phosphorylation of key targets like 4E-BP and S6K.
Purpose of the Study:
- To elucidate the role of mRNA translation control in cellular processes.
- To highlight the significance of the PI3K/Akt/mTOR pathway in regulating mRNA translation.
- To explore the therapeutic potential of targeting cap-dependent translation in cancer.
Main Methods:
- Analysis of mRNA translation regulation mechanisms.
- Investigation of signaling pathways, specifically PI3K/Akt/mTOR.
- Examination of downstream targets such as 4E-BP and S6K phosphorylation.
Main Results:
- mRNA translation control is a critical determinant of cell metabolism and function.
- The PI3K/Akt/mTOR pathway is a key regulator of mRNA translation.
- Inhibitors targeting this pathway demonstrate potential in cancer therapy.
Conclusions:
- Precise control of mRNA translation is essential for cellular homeostasis and response to stimuli.
- The PI3K/Akt/mTOR pathway's role in translation offers a viable target for therapeutic intervention.
- Inhibiting cap-dependent translation via this pathway presents a promising strategy for cancer treatment.
Related Concept Videos
03:03mTOR Signaling and Cancer Progression
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
03:03mTOR Signaling and Cancer Progression
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
01:22PI3K/mTOR/AKT Signaling Pathway
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a rapamycin-insensitive companion...
02:33Initiation of Translation
Initiating translation is complex because it involves multiple molecules. Initiator tRNA, ribosomal subunits, and eukaryotic initiation factors (eIFs) are all required to assemble on the initiation codon of mRNA. This process consists of several steps that are mediated by different eIFs.
First, the initiator tRNA must be selected from the pool of elongator tRNAs by eukaryotic initiation factor 2 (eIF2). The initiator tRNA (Met-tRNAi) has conserved sequence elements including modified bases at...
First, the initiator tRNA must be selected from the pool of elongator tRNAs by eukaryotic initiation factor 2 (eIF2). The initiator tRNA (Met-tRNAi) has conserved sequence elements including modified bases at...
02:33Initiation of Translation
Initiating translation is complex because it involves multiple molecules. Initiator tRNA, ribosomal subunits, and eukaryotic initiation factors (eIFs) are all required to assemble on the initiation codon of mRNA. This process consists of several steps that are mediated by different eIFs.
First, the initiator tRNA must be selected from the pool of elongator tRNAs by eukaryotic initiation factor 2 (eIF2). The initiator tRNA (Met-tRNAi) has conserved sequence elements including modified bases at...
First, the initiator tRNA must be selected from the pool of elongator tRNAs by eukaryotic initiation factor 2 (eIF2). The initiator tRNA (Met-tRNAi) has conserved sequence elements including modified bases at...
01:33Cancer-Critical Genes I: Proto-oncogenes
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...